Biotech · Private company
Portola Pharmaceuticals
Track this companyFree. Adds Portola Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials161 recruiting or active
Pipeline programs25From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline25
- AndexanetPhase 3 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- BetrixabanPhase 3 · Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
- EnoxaparinPhase 3 · Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
- Andexanet alfaPhase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- Andexanet alfa (bolus)Phase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- Andexanet alfa (infusion IV)Phase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- ApixabanPhase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- betrixabanPhase 2 · Atrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- Betrixaban 80 mg PO QDPhase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- clopidogrelPhase 2 · Percutaneous Coronary InterventionClinicalTrials.gov · fetched Nov 12, 2026
- EdoxabanPhase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- PRT060128Phase 2 · Percutaneous Coronary InterventionClinicalTrials.gov · fetched Nov 12, 2026
- PRT064445/ApixabanPhase 2 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- PRT064445/EnoxaparinPhase 2 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- RivaroxabanPhase 2 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- WarfarinPhase 2 · Atrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- Andexanet alfa (Gen 1 Process 2)Phase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- Andexanet alfa (Gen 2)Phase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- Apixaban 5 MGPhase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- BetrixabanPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Edoxaban 60 MGPhase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- ElinogrelPhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Enoxaparin sodiumPhase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
- PRT064445Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Rivaroxaban 20 MGPhase 1 · BleedingClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)NA · RECRUITING · started Feb 1, 2019ClinicalTrials.gov NCT03728166 · fetched Nov 12, 2026
- BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding OutcomesWITHDRAWN · started Sep 1, 2018ClinicalTrials.gov NCT03613402 · fetched Nov 12, 2026
- The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa AntagonistPHASE1 · COMPLETED · started Nov 16, 2017ClinicalTrials.gov NCT03397888 · fetched Nov 12, 2026
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsPHASE2 · COMPLETED · started Aug 28, 2017ClinicalTrials.gov NCT03310021 · fetched Nov 12, 2026
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaPHASE1 · COMPLETED · started Feb 26, 2017ClinicalTrials.gov NCT03083704 · fetched Nov 12, 2026
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban DosingPHASE2 · TERMINATED · started Aug 6, 2015ClinicalTrials.gov NCT03330457 · fetched Nov 12, 2026
- A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of RivaroxabanPHASE3 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02220725 · fetched Nov 12, 2026
- A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of ApixabanPHASE3 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02207725 · fetched Nov 12, 2026
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLPHASE1_PHASE2 · COMPLETED · started Aug 30, 2013ClinicalTrials.gov NCT01994382 · fetched Nov 12, 2026
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)PHASE2 · COMPLETED · started Dec 1, 2012ClinicalTrials.gov NCT01758432 · fetched Nov 12, 2026
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)PHASE2 · COMPLETED · started Dec 1, 2012ClinicalTrials.gov NCT03551730 · fetched Nov 12, 2026
- Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor AntidotePHASE1 · COMPLETED · started Jun 1, 2012ClinicalTrials.gov NCT03218241 · fetched Nov 12, 2026
- Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)PHASE3 · COMPLETED · started Mar 1, 2012ClinicalTrials.gov NCT01583218 · fetched Nov 12, 2026
- Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal ImpairmentPHASE1 · TERMINATED · started Sep 1, 2009ClinicalTrials.gov NCT00984113 · fetched Nov 12, 2026
- A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCIPHASE2 · COMPLETED · started Dec 1, 2008ClinicalTrials.gov NCT00751231 · fetched Nov 12, 2026
- Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to WarfarinPHASE2 · COMPLETED · started Oct 1, 2008ClinicalTrials.gov NCT00742859 · fetched Nov 12, 2026